Trend Report: DE&I in Clinical Research: Where we are Today
Recent FDA draft guidance and FDORA legislation have highlighted the urgency of improving representation of diverse populations in clinical trials.
- Prevalence of diversity plan submissions since FDA’s 2022 guidance
- Organizational definitions of DE&I from sites, sponsors, and CROs
- How the community is budgeting for and utilizing efforts to increase trial diversity
- Impact of efforts to increase trial diversity
Download the report to find out what’s been done so far, and where we have room to grow.
DATE
Time: 1 p.m. ET, 12 p.m. CT, 10 a.m. PT
Duration: 1 hour